跳转至内容
Merck
CN

SML3823

Sigma-Aldrich

KCI807

≥98% (HPLC)

别名:

5,3’-Dihydroxyflavone, 5-Hydroxy-2-(3-hydroxyphenyl)-4H-1-benzopyran-4-one

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C15H10O4
CAS号:
分子量:
254.24
MDL编号:
UNSPSC代码:
51111800
UNSPSC代码:
12352200
NACRES:
NA.77

质量水平

方案

≥98% (HPLC)

表单

powder

颜色

white to beige

溶解性

0.2 mg/mL (DMSO:EtOH (2:1),clear, warmed, clear colorless solution)

储存温度

room temp

SMILES字符串

[o]1c2c([c](cc1c3cc(ccc3)O)=O)c(ccc2)O

InChI key

SZMQXDYEGKRZDG-UHFFFAOYSA-N

生化/生理作用

KCI807 is a cell penetrant, selective and potent inhibitor of the androgen receptor (AR)-ELK1 interaction. KCI807 interrupts association of the androgen receptor (AR) with transcription activator ELK1 (ETS family transcription factor ELK1). It potently suppresses growth of enzalutamide-resistant prostate cancer tumor xenografts in rodents.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

The Small Molecule Antagonist KCI807 Disrupts Association of the Amino-Terminal Domain of the Androgen Receptor with ELK1 by Modulating the Adjacent DNA Binding Domain
Molecular Pharmacology, 103(4), 211-220 (2023)
Rayna Rosati et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 24(24), 6509-6522 (2018-09-07)
Testosterone suppression in prostate cancer is limited by serious side effects and resistance via restoration of androgen receptor (AR) functionality. ELK1 is required for AR-dependent growth in various hormone-dependent and castration-resistant prostate cancer models. The amino-terminal domain of AR docks

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门